ArriVent names Brent Rice as chief commercial officer

ArriVent BioPharma Inc. (NASDAQ: AVBP) announced the appointment of Brent S. Rice as chief commercial officer. Rice brings over 25 years of commercial experience in the biotechnology and pharmaceutical industry to the clinical-stage biopharmaceutical company.

Rice most recently served as senior vice president and global chief commercial officer at Autolus Therapeutics Ltd., where he led global commercialization and commercial strategy. At Autolus, he built the U.S. organization and led the launch of the company's first commercial product, helping transition the company from clinical-stage development to a commercial organization.

"Brent brings a proven track record in launching novel therapies, building high-performing organizations, and leading strategic pipeline planning," said Bing Yao, chairman and chief executive officer of ArriVent.

The appointment comes as ArriVent prepares for potential approval and commercialization of firmonertinib for EGFR mutant non-small cell lung cancer. The company is also developing a portfolio of antibody drug conjugates.

Prior to Autolus, Rice led managed markets at Juno Therapeutics, where he developed payer and reimbursement strategy capabilities. He spent 18 years at Amgen in roles of increasing responsibility across marketing, operations, and reimbursement functions.

ArriVent is headquartered in Newtown Square, Pennsylvania, and focuses on developing differentiated medicines for patients with cancers. The information is based on a company press release.

You May Also Be Interested In

• Definitive Healthcare names Clay Ritchey as new CEO
• cbdMD agrees to acquire Twinlab brands in court-pending deal
• Vox Royalty to acquire 2% gold royalty at White Dam for A$5M